JPET Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kreek, M. J.
Right arrow Articles by Ho, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kreek, M. J.
Right arrow Articles by Ho, A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*NALMEFENE
*NALOXONE
*NALTREXONE

Vol. 288, Issue 1, 260-269, January 1999

Dynorphin A1-13 Causes Elevation of Serum Levels of Prolactin Through an Opioid Receptor Mechanism in Humans: Gender Differences and Implications for Modulation of Dopaminergic Tone in the Treatment of Addictions

M. J. Kreek, J. Schluger, L. Borg, M. Gunduz and A. Ho

Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, New York

Dynorphin peptides act preferentially at kappa - as well as µ- and delta -opioid receptors. This study was conducted to determine whether dynorphin peptides act to lower dopaminergic tone in the tuberoinfundibular system, resulting in elevated serum prolactin levels and, if so, whether such an effect is mediated by the opioid receptors. Dose-related increases in serum prolactin levels were observed after dynorphin A1-13 was administered i.v. in doses of 120 and 500 µg/kg to healthy human volunteers with no history of drug or alcohol abuse. Studies were then conducted to determine whether this effect is opioid receptor mediated and, if so, whether at kappa - or µ types. Pretreatment with the opioid antagonist nalmefene (30 mg i.v.), which has high affinity at both µ- and kappa -opioid receptors, caused a greater attenuation in dynorphin A1-13-stimulated increases in serum prolactin levels than pretreatment with similarly high doses of naloxone, an antagonist with lower affinity for both µ- and kappa -opioid receptors. These results suggest dynorphin A1-13 lowers tuberoinfundibular dopaminergic tone through action at kappa - and possibly µ-opioid receptors. Female subjects were significantly more responsive to the prolactin effects of dynorphin than were male subjects. Dynorphin gene expression, dynorphin peptides, and kappa -opioid receptor gene expression and binding have been shown to be altered in response to cocaine administration. Also, both dynorphin peptides and synthetic kappa -opioid agonists have been shown to lower dopamine levels in the nucleus accumbens and to attenuate cocaine-induced surges in dopamine levels. Thus, a dynorphin-like compound capable of reaching critical mesolimbic-mesocortical and nigrostriatal dopaminergic systems may be effective in the management of cocaine addiction.


0022-3565/99/2881-0260$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
E. R. Butelman, S. Rus, D. S. Simpson, A. Wolf, T. E. Prisinzano, and M. J. Kreek
The Effects of Herkinorin, the First {micro}-Selective Ligand from a Salvinorin A-Derived Scaffold, in a Neuroendocrine Biomarker Assay in Nonhuman Primates
J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 154 - 160.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
E. R. Butelman, M. Mandau, K. Tidgewell, T. E. Prisinzano, V. Yuferov, and M. J. Kreek
Effects of Salvinorin A, a {kappa}-Opioid Hallucinogen, on a Neuroendocrine Biomarker Assay in Nonhuman Primates with High {kappa}-Receptor Homology to Humans
J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 300 - 306.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
G. Bart, L. Borg, J. H. Schluger, M. Green, A. Ho, and M. J. Kreek
Suppressed Prolactin Response to Dynorphin A1-13 in Methadone-Maintained Versus Control Subjects
J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 581 - 587.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
N. Ben-Jonathan and R. Hnasko
Dopamine as a Prolactin (PRL) Inhibitor
Endocr. Rev., December 1, 2001; 22(6): 724 - 763.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
E. R. Butelman, M. C. H. Ko, J. R. Traynor, J. A. Vivian, M.-J. Kreek, and J. H. Woods
GR89,696: A Potent kappa -Opioid Agonist with Subtype Selectivity in Rhesus Monkeys
J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1049 - 1059.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.